Skip to content
Search

Latest Stories

Future of digital healthcare

Gianpiero Celino outlines a vision for the future of digital healthcare building on the huge progress made by the NHS during the Coronavirus pandemic...

Collectively, the NHS must embrace the lessons learned from the Covid-19 pandemic, which saw mass adoption of digital tools and solutions to provide continuity of care in extraordinary circumstances. Despite the mass rollout of the vaccine, we still have to continue to maximise these tools to manage the backlog of care that has accrued.


There is now a recognition that healthcare, and particularly primary care can be delivered in a more modern, efficient and responsive way – and this relies in part on the ability for data to flow beyond traditional boundaries.

It also relies on the ability to connect different elements of primary and community care –community pharmacy; GP practices; and Out of Hospital care – to facilitate better shared and proactive/preventative care.

Collaboration

The NHS response to the pandemic accelerated so much more than the use of new digital technologies. Yes, PMR enhancements such as one click access to the Summary Care Record and Real-Time Exemption Checking, remote access, and prescription delivery tracking applications were fast-tracked.

This met with both immediate needs to provide continuity of patient care and essential time savings and will provide a foundation for the evolution of the way patients and pharmacists interact and the services that can be provided. However, even more importantly for the future of community and primary care services, the response revealed what can be achieved with the right attitude, commitment and collaborative approach.

Barriers were overcome, bureaucracy thrown aside and the delays that typically dog NHS IT development disappeared. NHSX’s immediate issuing of guidance on privacy and data protection, for example, was a vital intervention that saved huge amounts of time and advanced the deployment of new technologies.

Of course, no one is suggesting the solutions deployed in response to the crisis are perfect. They have, however, provided a tantalizing view of what digital technologies can and must enable within primary and community care – and now is the chance to ‘build back better’ throughout the NHS.

Digital future

So what must change and what can be achieved? Given the pace of technological evolution over the past decade, it is a shame that the digital technologies still largely lag behind the way pharmacists want to deliver patient services.

An extraordinary level of collaboration had already been achieved across an entire network of health care providers well before the pandemic hit – and the way the NHS had to respond to the virus highlighted the value of that cooperative model. From GPs, nurse practitioners and pharmacists that play a key role within practices, to the hospital consultants, care homes, opticians and dentists, the concept of working together as a team to look after patients is now firmly established.

Technology must adapt to support that clinical imperative. Some progress had been made pre-COVID. At a GP practice level, collaboration is well supported by GP clinical systems that share patient information across teams within a practice. However, as yet, there is no good, wide scale adoption of systems that allow true shared care to happen across multiple GP practices, local authorities and community care services. This is the urgent issue that needs to be addressed as a priority for 2021.

Health economy

The need for, and challenges associated with, data sharing across a wider health economy have been highlighted by the Covid-19 mass vaccination programme which demands multi-disciplinary co-operation across a wide health economy. Safely vaccinating as many as one thousand patients at a time bears no relation to the ten or so flu vaccinations undertaken daily within a GP practice and will require the collaboration of many different service providers.

This emphasises what is required to achieve truly effective team working across the wider health economy. The technology needs to support individuals working in different locations, while still using familiar systems and working methods to minimise disruption.

It needs to ensure individual health care providers have instant access to useful additional patient information wherever they are from GP surgery to dedicated clinics, community pharmacy and patient home. And, critically, the concept of the GP record as the single version of patient truth must remain at the heart of this collaborative model.

This approach works for both clinicians and patients. It supports the essential and growing role that community care providers play and provides a seamless link between primary and secondary care.

Proactive care

The big patient win is that this collaborative approach creates a team of healthcare providers acting as one, coordinating and sharing and collaborating to deliver the right care at the right time. And it changes the model away from one based on intermittent, appointment or prescription led patient interaction to one where the multi-disciplinary team can undertake a programme of continuous patient review.

The management of Type 2 diabetes is a prime example of a complex condition that requires a multi-disciplinary team involving doctors, consultants, pharmacists, diabetes nurses and health educators. These patients require regular review – but there are also significant advantages associated with continuous support that does not require a specific appointment.

On top of the standard annual review, effective data sharing between both health care providers and the patient enables the entire team to collaborate throughout the year. Frequent updates about how the patient’s diabetes is being controlled means team members– across the local health economy– can embrace proactive care by suggesting changes to diet, lifestyle or medication at any time.

Local Technology gaps

This multi-disciplinary way of delivering patient care is the current and future direction of travel for primary and community care. The priority for 2021 is to address the technology gaps revealed by the Covid-19 NHS response and to use that knowledge to achieve a wider adoption of a broad, effective community care model. In addition, that means focusing very specifically on what must be delivered – and ensuring the barriers that have been broken down are not recreated.

Healthcare professionals’ expectations were raised during the pandemic. Community pharmacists want IT suppliers and systems that will change and flex to support service delivery throughout a wider health economy.

They are expecting innovation and rapid delivery of new solutions that work immediately in these new settings. They want not just PMR systems, but digital technologies that allow them to become more efficient, provide additional value-added services, and deliver collaboration at scale to look after patients throughout the wider health economy.

And that can only be achieved with the commitment of all the stakeholders within each local health economy.

Gianpiero Celino is clinical director at Cegedim Healthcare Solutions.

More For You

How to leverage data to drive pharmacy growth

Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy.

Pharmacy challenges: How data can help spot the ‘elephant in the room’

Adopting new technologies is vital for moving pharmacy forward — but are you fully harnessing the data these tools generate?

“Being able to utilise, manage, and interpret the data these technologies provide can help add more value to your business,” said Adele Curran, chief operating officer at Real World Analytics (RWA) Pharmacy, while speaking at the recent Pharmacy Business Conference.

Keep ReadingShow less
Branded OTC products can boost pharmacy revenue and promote self-care, says PAGB CEO

Michelle Riddalls

How branded OTC products can help struggling community pharmacies - PAGB chief explains

Branded over-the-counter (OTC) products could play a vital role in promoting self-care and supporting the sustainability of community pharmacies, said Michelle Riddalls, CEO of PAGB – the consumer healthcare association – during the recent Pharmacy Business Conference.

Riddalls emphasised that OTC medicines not only enable consumers to better manage their health through self-care but also offer pharmacies an opportunity to increase revenue, particularly during a time of mounting financial pressure.

Keep ReadingShow less
How Peptides Are Transforming Modern Drug Development

Modern Drug Development

How Peptides Are Transforming Modern Drug Development

The pharmaceutical industry is rapidly evolving, embracing new technologies and methodologies. Peptides are emerging as a crucial component in this transformation, offering innovative solutions to drug development. This shift is not only reshaping how drugs are discovered but also enhancing their efficacy and safety.

In recent years, the pharmaceutical landscape has undergone significant changes, driven by advancements in technology and scientific understanding. One of the most promising areas of innovation is the use of peptides in drug development. These short chains of amino acids have proven to be versatile tools, capable of targeting specific cells or molecules with high precision. In this context, certain bpc 157 peptide research peptides have been highlighted for their potential applications in various therapeutic areas, showcasing the promise that peptides hold for modern pharmaceutical studies.

Keep ReadingShow less
Off-patent medicines could save NHS millions—but only if UK remains attractive to suppliers - BGMA

BGMA chief executive Mark Samuels urges government to back off-patent medicines ahead of Life Sciences Plan release.

UK risks losing millions in NHS savings without stronger support for generics - BGMA

The British Generic Manufacturers Association (BGMA) has called on the government to create a more supportive environment for the generics and biosimilars sector, warning that the UK risks missing out on significant NHS savings arising from new off-patent medicines.

According to the BGMA, 31 medicines are due to lose patent protection between January and June 2025, with a further 28 set to follow in the second half of the year.

Keep ReadingShow less
Support for generic medicines manufacturers key to affordable healthcare- Teva UK director

Teva UK sounds alarm on accelerating consolidation of critical generic medicines

Photo credit: gettyimages

Exclusive: Teva UK calls for inclusion of generic manufacturers in policy talks

A healthy and vibrant generics marketplace supports not only patients but also contributes billions of pounds in savings to the drugs bill. However, growing pressures on generic medicine manufacturers could threaten this vital part of the healthcare ecosystem, warns Ryan Ruscoe, senior director of generics and OTC at Teva UK.

Speaking exclusively to Pharmacy Business, Ruscoe stressed the urgent need to address supply chain vulnerabilities, particularly for critical generic medicines.

Keep ReadingShow less